Omega Therapeutics IPO Presentation Deck

Mouse 1 In vivo MoA in Oncology Program - HCC Program HCC tumors from xenograft model treated with OEC candidate effected regulation of MYC(↓), Ki67(↓) and Caspase-3 (1) Mouse 2 MYC OEC candidate treated Caspase 3 ©2021 Omega Therapeutics, Inc. Ki67 Mouse 3 Mouse 4 Protein present MYC Negative control Caspase 3 Ki67 22

View entire presentation